Trial record 1 of 2 for:    NCT02702180
Previous Study | Return to List | Next Study

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (IMPALA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02702180
Recruitment Status : Recruiting
First Posted : March 8, 2016
Last Update Posted : April 12, 2018
Information provided by (Responsible Party):
Savara Inc.

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 2019
  Estimated Study Completion Date : September 2019